Dr. Robert Kyle, MD, defined and determined both the term MGUS and smoldering myeloma. Dr. Kyle founded the Mayo Clinic’s Myeloma, Amyloidosis and Dysproteinemia Clinic. He founded a special protein laboratory and began collecting a recording data for patients with monoclonal plasma cell disorders. He has written 890 peer-reviewed articles and over 1,200 abstracts. Dr. Kyle received the top two awards in hematology, one from the American Society of Clinical Oncology and one from the American Society of Hematology. They are the highest honors bestowed by these two groups and he is the only doctor to have received both. Dr. Kyle is a director and member of the Scientific Advisory Board for the International Myeloma Foundation. He has been Chairman of the Myeloma Committee for the Eastern Cooperative Oncology Group, the Secretary General of the International Society of Hematology Inter-American Division, and a member of the editorial board of the journal Leukemia. The International Myeloma Foundation has created a Robert A. Kyle Lifetime Achievement Award to honor the physician who most exemplifies a singular dedication to and compassion for myeloma patients and the treatment of their disease. His research continues at the Mayo Clinic today.

Thanks to our episode sponsor, Takeda Oncology.